Oral Hydroxychloroquine is safe and effective in treating primary Sjögren’s syndrome-related dry eye disease
Chitinase-3 like-protein-1 may serve as a potential biomarker in RA patients with interstitial lung disease
SENSCIS trial shows nintedanib reduces the decline of lung function in patients with limited cutaneous systemic sclerosis and ILD
